Are All Botulinum Toxin Type A Products the Same?

No.

Botulinum toxin type A products share the same broad pharmacologic principle: the active neurotoxin ultimately inhibits acetylcholine release from cholinergic nerve terminals.

However, sharing a mechanism of action does not make different commercial products identical medicines.

Clinically used BoNT-A products can differ in:

• manufacturing processes;

• neurotoxin preparation;

• formulation;

• excipients;

• presence or absence and characteristics of associated proteins;

• potency assays;

• reference standards;

• labeled potency units;

• approved indications;

• recommended dosing;

• storage and preparation requirements; and

• supporting clinical evidence. [1–5]

For this reason, product comparison should separate what is known about the formulation from what has actually been demonstrated clinically.

What Does “Formulation” Mean?

A pharmaceutical formulation describes the components and presentation of the finished medicinal product.

For BoNT-A, this can include:

• the active botulinum neurotoxin preparation;

• proteins associated with the neurotoxin preparation;

• stabilizing excipients;

• sodium chloride or other formulation components;

• the labeled potency;

• vial presentation; and

• requirements for reconstitution and storage.

Published reviews have documented compositional differences among clinically used botulinum toxin products. [2,3]

A formulation table can therefore provide useful factual information.

However, formulation data alone cannot establish comparative clinical efficacy.

What Are Excipients?

Excipients are components included in a pharmaceutical formulation other than the active ingredient.

They may serve functions such as stabilization, maintaining product integrity or supporting the finished pharmaceutical preparation.

Different BoNT-A products may contain different excipients or different amounts of formulation components. [2]

These differences are legitimate characteristics to include in a factual product comparison.

However:

different excipients do not automatically mean better efficacy

and

similar excipients do not prove clinical equivalence.

Clinical claims require clinical evidence.

What Are Complexing or Associated Proteins?

Native botulinum neurotoxin can exist in association with non-toxic proteins.

Commercial BoNT-A preparations differ in whether and how these associated proteins are present in the finished preparation. [2,4]

This is a genuine formulation difference.

However, the clinical significance of a compositional difference must be demonstrated rather than assumed.

For example, formulation differences should not automatically be converted into claims of:

• greater efficacy;

• longer duration;

• less diffusion;

• better safety; or

• lower immunogenicity.

Those questions require relevant clinical or immunogenicity evidence.

Why Does Manufacturing Matter?

Botulinum toxin products are biological medicines.

For biologics, the manufacturing process is closely connected to the characteristics of the finished product.

Manufacturing may involve product-specific methods for toxin production, purification, formulation, filling, stability control and potency determination. [3–5]

This differs from the simplified idea that all BoNT-A products contain one universally standardized chemical substance that can be compared solely by the number printed on the vial.

Product identity therefore extends beyond the words “botulinum toxin type A.”

Why Do Potency Assays Matter?

A labeled BoNT-A Unit is a measure of biological activity rather than a conventional mass measurement such as milligrams.

Potency is determined using product-specific biological reference systems and assays.

Historical experimental work has shown that assay conditions can influence measured potency and that different formulations may respond differently to those conditions. [6]

Modern reviews continue to emphasize that proprietary manufacturing, reference standards and potency-assay characteristics contribute to product-specific units. [3,5]

Therefore:

100 U of one BoNT-A product should not automatically be interpreted as biologically identical to 100 U of another product.

BW-12 examines this issue in greater depth.

Does the Same Number of Units Mean the Same Amount of Toxin?

Not necessarily.

A Unit represents biological potency as defined for a specific product and assay system.

It is not a universal measure of toxin mass.

Two products labeled with the same numerical number of Units may differ in neurotoxin content, formulation and potency-testing system. [3,5]

This is one reason direct cross-product dose conversion requires caution.

Can Products Be Compared by Protein Content Alone?

Protein-content measurements can describe a physical or biochemical characteristic of a preparation.

They do not independently establish clinical potency.

Similarly, the amount of 150-kDa neurotoxin measured in a vial does not by itself determine the clinical dose, efficacy, duration or safety of that product.

Those clinical questions require evidence generated under relevant treatment conditions.

Formulation science can explain why products should not automatically be considered identical.

It does not replace clinical trials.

Does Similar Formulation Mean Similar Clinical Performance?

Not necessarily.

Two products could share some formulation characteristics while differing in manufacturing, potency assays, labeled units or clinical evidence.

Conversely, two products with formulation differences may still produce comparable outcomes when tested at defined doses in an appropriately designed clinical trial.

Therefore, similarity should be demonstrated at the level relevant to the claim being made.

Formulation similarity is a formulation claim.

Clinical comparability is a clinical claim.

They are not interchangeable.

Can Clinical Outcomes Be Compared Across Products?

Yes, when the evidence is designed to answer that question.

The most informative evidence is generally a direct comparative clinical trial in which:

• the products are clearly identified;

• doses are predefined;

• the indication is defined;

• patients are appropriately randomized;

• endpoints are prespecified;

• follow-up is appropriate; and

• the statistical hypothesis is clearly stated.

If a non-inferiority trial demonstrates non-inferiority for a defined endpoint, that conclusion applies to the studied products, dose relationship, population, endpoint and protocol.

It does not automatically create a universal equivalence or conversion rule.

What Does Neuronox Contain?

According to the product information used in the BotoxWiki evidence set, Neuronox is a botulinum toxin type A preparation formulated with human serum albumin and sodium chloride as excipients.

This is useful factual formulation information.

It tells us what the product contains.

It does not, by itself, tell us that Neuronox is more effective, longer-lasting, safer or clinically interchangeable with another product.

Those questions must be answered using product-specific clinical evidence.

Why Is Neuronox Particularly Useful as an Example?

Neuronox illustrates why formulation information and clinical evidence should be considered separately.

The product can be described at the formulation level.

But Neuronox also has published randomized comparative trials in multiple clinical settings, including:

• moderate-to-severe glabellar lines;

• essential blepharospasm;

• cerebral-palsy-associated spastic equinus; and

• post-stroke upper-limb spasticity. [7–10]

This means Neuronox does not need to be evaluated solely by asking whether its formulation “looks similar” to another BoNT-A product.

There is product-specific clinical evidence that can be examined directly.

What Did the Glabellar Trial Add?

The randomized, double-blind Phase III glabellar study compared Neuronox/NBoNT with onabotulinumtoxinA at the doses defined in the protocol. [7]

At week 4, investigator-assessed responder rates at maximum frown were:

Neuronox/NBoNT: 93.7%

onabotulinumtoxinA: 94.5%.

The trial met its prespecified non-inferiority criterion.

This is more informative for that clinical question than simply comparing ingredient lists.

However, the result belongs to the studied protocol and does not establish universal product interchangeability.

What Do the Therapeutic Trials Add?

Randomized comparative studies also evaluated Neuronox/Meditoxin in:

essential blepharospasm [8]

spastic equinus gait in children with cerebral palsy [9]

and

post-stroke upper-limb spasticity. [10]

The primary analyses of these studies met their respective prespecified non-inferiority criteria.

These trials demonstrate an important evidence principle:

clinical comparability should be established from clinical studies rather than inferred from formulation similarity alone.

Can the Dose Relationships Used in Neuronox Trials Be Applied Everywhere?

No.

If a clinical trial compares two products at a particular numerical dose relationship, the result demonstrates what occurred under that study protocol.

It does not automatically establish that the same numerical relationship should be used:

• in another indication;

• in another muscle;

• at another total dose;

• in another population; or

• with another administration technique.

This distinction is especially important because BoNT-A potency units are product-specific.

Can We Rank Products by Formulation?

A factual table can compare formulation characteristics.

For example, a table may include:

Comparison Domain

Appropriate Question

Active preparation

What BoNT type/preparation is identified?

Excipients

What formulation components are listed?

Presentation

What vial strengths are approved?

Potency

How are labeled units defined?

Storage

What does the product label require?

Reconstitution

What preparation instructions are approved?

Indications

What uses are locally approved?

Clinical evidence

What trials exist for the product?

What should generally be avoided is converting these factual differences into unsupported rankings such as:

“best formulation”

“strongest toxin”

“purest therefore best”

“lowest diffusion”

or

“safest formulation.”

Such conclusions require evidence designed to test those specific outcomes.

Does “Purity” Automatically Predict Better Clinical Results?

No.

Terms such as “pure,” “high purity” or “protein load” may refer to particular biochemical or manufacturing characteristics.

A biochemical characteristic should not automatically be translated into superior clinical efficacy, duration or safety.

If a manufacturer or publication makes a purity claim, the reader should ask:

What exactly was measured?

By which method?

Against what comparator?

and

Has the difference been shown to affect a clinically relevant outcome?

Without that bridge, the statement remains a formulation or laboratory observation rather than a clinical conclusion.

Does Formulation Determine Diffusion?

Formulation may be one of several factors discussed in relation to local distribution, but clinical spread cannot be reduced to formulation alone.

Dose, concentration, injection volume, muscle anatomy, target selection and injection technique may also influence the observed clinical effect. [1]

Claims that one product “does not spread” or “diffuses less” require direct evidence under controlled conditions.

This topic is examined in detail in BW-13.

Does Formulation Determine Duration?

Not by itself.

Clinical duration depends on how duration is defined and measured, the indication, dose, endpoint, patient population and treatment protocol.

A compositional difference alone cannot establish longer clinical duration.

Duration claims should be supported by clinical studies specifically capable of evaluating duration.

BW-14 addresses this issue separately.

What Is the Best Way to Compare BoNT-A Products?

A strong comparison should proceed in layers.

Layer 1: Product Identity

Identify the exact product and current approved product information.

Layer 2: Formulation

Document the active preparation, excipients, presentation and relevant pharmaceutical characteristics.

Layer 3: Potency Units

Treat units as product-specific and avoid automatic conversion.

Layer 4: Regulatory Information

Compare approved indications, dosing, warnings, preparation and storage in the relevant jurisdiction.

Layer 5: Clinical Evidence

Review direct randomized studies, study populations, dose relationships, endpoints and follow-up.

Layer 6: Safety Evidence

Assess adverse-event reporting within the relevant clinical setting.

Layer 7: Evidence Quality

Review study design, statistical hypothesis, sample size, sponsorship and conflicts of interest.

This framework is more reliable than comparing products using a single marketing feature.

What Can Be Compared Directly?

Appropriate factual comparisons may include:

• labeled ingredients;

• excipients;

• vial presentations;

• approved indications;

• storage instructions;

• reconstitution instructions;

• published study designs;

• studied doses;

• endpoints;

• response rates within defined studies;

• adverse events within defined studies; and

• funding or conflict-of-interest disclosures.

These are identifiable facts.

What Should Not Be Assumed?

Without appropriate evidence, do not assume:

• equal Units;

• universal dose conversion;

• identical efficacy;

• identical duration;

• identical diffusion;

• identical safety;

• identical immunogenicity;

• universal interchangeability; or

• superiority based on formulation alone.

Frequently Asked Questions

Are all BoNT-A products basically the same drug?

They share a broad mechanism of action, but commercial products have product-specific manufacturing, formulations, potency assays, labeled units and evidence.

If two products contain human serum albumin, are they equivalent?

No. Sharing an excipient does not establish clinical equivalence.

If two products were compared at the same numerical Units in a trial, does that prove 1:1 conversion?

No. It shows the outcome under that specific study protocol.

Does a similar ingredient list prove similar duration?

No.

Does a head-to-head trial provide stronger comparative evidence than a formulation table?

For a clinical efficacy question, yes. A properly designed direct comparative clinical trial is more relevant than inferring clinical performance from ingredients alone.

What is important about Neuronox?

Neuronox has identifiable formulation information and published randomized comparative clinical evidence across several indications. [7–10]

This allows the product to be evaluated using its own clinical data rather than formulation assumptions alone.

Bottom Line

BoNT-A products share a common pharmacologic class but should not be treated as identical formulations.

Manufacturing, excipients, associated proteins, potency assays, labeled units, approved indications and clinical evidence can differ across products. [1–6]

A formulation comparison can establish what is in a product.

It cannot by itself establish how two products compare clinically.

For Neuronox, this distinction is particularly important because the product has both identifiable formulation information and published randomized comparative evidence in aesthetic and therapeutic settings. [7–10]

The strongest evidence-based approach is therefore:

describe formulation from authoritative product information, treat Units as product-specific, and use direct clinical studies when making clinical comparisons.

References

1. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;13(Suppl 1):2–10. doi:10.1111/j.1468-1331.2006.01438.x. PMID:16417591.

2. Pickett A, Perrow K. Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol. 2010;9(9):1085–1091. PMID:20865839.

3. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227–241. doi:10.2147/BTT.S65603. PMID:25336912.

4. Dressler D. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761–1768. doi:10.1080/09638280701568296. PMID:18033601.

5. Update on Non-Interchangeability of Botulinum Neurotoxin Products. 2024. PMID:38922160.

6. Pickett AM, Hambleton P. Therapeutic botulinum toxin type A: factors affecting potency. Toxicon. 1995;33(10):1359–1368. doi:10.1016/0041-0101(96)00070-0. PMID:8896190.

7. Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072. PMID:23301821.

8. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137.

9. Kim K, Shin HI, Kwon BS, Kim SJ, Jung IY, Bang MS. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x.

10. Seo HG, Paik NJ, Lee SU, Oh BM, Chun MH, Kwon BS, Bang MS. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633.

11. NEURONOX (Botulinum toxin Type A) Thai Product Information. Revised April 3, 2023.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.